Midodrine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
| Line 34: | Line 33: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Midodrine is a [[prodrug]] which forms an active [[metabolite]], desglymidodrine, which is an [[Alpha-1 adrenergic receptor|α<sub>1</sub>-receptor]] [[agonist]] and exerts its actions via activation of the [[alpha-adrenergic receptor]]s of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac [[beta-adrenergic receptor]]s. Desglymidodrine diffuses poorly across the [[blood–brain barrier]], and is therefore not associated with effects on the [[central nervous system]]. | Midodrine is a [[prodrug]] which forms an active [[metabolite]], desglymidodrine, which is an [[Alpha-1 adrenergic receptor|α<sub>1</sub>-receptor]] [[agonist]] and exerts its actions via activation of the [[alpha-adrenergic receptor]]s of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac [[beta-adrenergic receptor]]s. Desglymidodrine diffuses poorly across the [[blood–brain barrier]], and is therefore not associated with effects on the [[central nervous system]]. | ||
==Metabolism== | ==Metabolism== | ||
| Line 47: | Line 44: | ||
==Side effects== | ==Side effects== | ||
Headache; feeling of pressure/fullness in the head, vasodilation/flushing face, confusion/thinking abnormality, dry mouth; nervousness/anxiety and rash. | Headache; feeling of pressure/fullness in the head, vasodilation/flushing face, confusion/thinking abnormality, dry mouth; nervousness/anxiety and rash. | ||
==References== | ==References== | ||
Revision as of 00:34, 24 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H18N2O4 |
| Molar mass | 254.282 g/mol |
|
WikiDoc Resources for Midodrine |
|
Articles |
|---|
|
Most recent articles on Midodrine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Midodrine at Clinical Trials.gov Clinical Trials on Midodrine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Midodrine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Midodrine Discussion groups on Midodrine Directions to Hospitals Treating Midodrine Risk calculators and risk factors for Midodrine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Midodrine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Midodrine (brand names Amatine, ProAmatine, Gutron) is a vasopressor/antihypotensive agent. Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension. In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, has failed to complete required studies after the medicine reached the market.[1][2]
In September 2010, the FDA reversed its decision to remove Midodrine from the market and has allowed it to remain available to patients while Shire plc collects further data regarding the efficacy and safety of the drug.[3] Shire plc announced on September 27, 2011 that it was continuing the process to work with the FDA towards a final approval of the drug.[4]
Chemical properties
Midodrine is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol.
Mechanism of action
Midodrine is a prodrug which forms an active metabolite, desglymidodrine, which is an α1-receptor agonist and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors. Desglymidodrine diffuses poorly across the blood–brain barrier, and is therefore not associated with effects on the central nervous system.
Metabolism
After oral administration, midodrine is rapidly absorbed. The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93%.
Indications
Midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension. In a critical care setting, it is widely used as an adjunctive therapy to weaning patients off of intravenous vasopressive medications. It has been suggested also as a treatment for chronic fatigue syndrome[5] as well as for hepato-pulmonary syndrome. It is also used with octreotide for hepatorenal syndrome; the proposed mechanism is constriction of splanchnic vessels and dilation of renal vasculature.
Contraindications
Midodrine is contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma or thyrotoxicosis. Midodrine should not be used in patients with persistent and excessive supine hypertension.
Side effects
Headache; feeling of pressure/fullness in the head, vasodilation/flushing face, confusion/thinking abnormality, dry mouth; nervousness/anxiety and rash.
References
- ↑ U.S. proposes withdrawal of Shire hypotension drug, Aug 16, 2010.
- ↑ O'Riordan, Michael. "FDA recommends withdrawal of midodrine". Food and Drug Administration. FDA proposes withdrawal of low blood pressure drug [press release]. August 16, 2010. TheHeart.org. Retrieved 1 April 2011..
- ↑ Midodrine (ProAmatine, generic) Proposed Market Withdrawal – Update September 10, 2010.
- ↑ Shire Announces Update on ProAmatime September 27, 2011.
- ↑ Naschitz J, Dreyfuss D, Yeshurun D, Rosner I (April 2004). "Midodrine treatment for chronic fatigue syndrome". Postgrad Med J. 80 (942): 230–2. doi:10.1136/pgmj.2003.011429. PMC 1742969. PMID 15082846.
External links
- Midodrine at drugs.com
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cardiovascular Drugs
- Drug